Publication Month: Mar 2023 | Report Code: TIPRE00029831 | No. of Pages: 214 | Category: Technology, Media and Telecommunications | Status: Published
The manufacturing execution system (MES) is a comprehensive, dynamic solution that helps track, monitor, document, and control the process of goods manufacturing, from raw materials to finished products. These solutions also provide decision-makers with multivariate data, which can be utilized for optimizing plant floor operations and enhancing production efficiency. In addition, implementing an MES in pharmaceutical manufacturing plants helps manufacturers improve scheduling and resource utilization, enhance manufacturing flexibility and process changeover, reduce work in progress (WIP), improve material tracking, shorten production cycles, lower production record errors, and minimize product recalls.
|Market Size Value in||US$ 3,139.14 million in 2022|
|Market Size Value by||US$ 10,456.54 million by 2033|
|Growth rate||CAGR of 12.0% from 2023 to 2033|
|No. of Pages||214|
|No. of Tables||119|
|No. of Charts & Figures||68|
|Historical data available||Yes|
|Segments covered||Offering, Deployment, Organization Size, and Application|
|Free Sample Copy Available|
The growing digitization in the pharmaceutical industry is raising the demand for Pharma 4.0 among the factors contributing to the growing manufacturing execution system in Life sciences market size. The model helps increase connectivity and productivity, simplify compliance, and marshal production information to respond to problems as they emerge. The Pharma 4.0 model helps transform the manufacturing process by connecting workers to more human-centric workflows. The International Society for Pharmaceutical Engineering (ISPE) and its members are developing a roadmap to introduce Pharma 4.0. The objective of the Pharma 4.0 model is to enable organizations to leverage the full potential of digitalization to provide faster therapeutic innovations and improve production processes for patients’ benefit.
Key players in the Pharma 4.0 ecosystem are collaborating to accelerate the adoption of the same. For instance, in March 2021, Lonza and NNIT announced a partnership to speed up MES projects. Under this partnership, the companies will combine Lonza’s MODA Platform with NNIT’s Accelerated Implementation Methodology. With this, the companies will get a complete Pharma 4.0 solution and achieve their digitalization vision faster than ever. Therefore, the increasing adoption of Pharma 4.0 boosts the manufacturing execution system in life sciences market growth.
Get more information on this report :
Based on region, the market manufacturing execution system market is classified into North America, Europe, Asia Pacific, South America, and the Middle East & Africa. North America dominated the manufacturing execution system in life sciences market share in 2022. The market in this region is further segmented into the US, Canada, and Mexico. North America is one of the developed regions. Pharmaceuticals, biotechnology, and many other industries in the region are known for the adoption of highly advanced technologies and automated operations. Pharmaceutical, medical device manufacturing, and biotechnology companies are implementing MES to improve the productivity and management of their production units. Companies such as Abbot, Baxter International, Genitope Corporation, and Merck & Co. Thus, the growing adoption of digital transformation is expected to boost the manufacturing execution system in life sciences market size in North America in the coming years.
The manufacturing execution system in life sciences market, by deployment, is segmented into cloud and on-premise. The on-premise segment held the larger manufacturing execution system in life sciences market share in 2022, but the cloud segment is expected to record a higher CAGR during the forecast period. The cloud segment is growing considerably due to several advantageous characteristics, such as scalability and cost-effectiveness. Cloud Native MES are offered in the form of a software-as-a-service (SaaS) solution that runs over the internet. Such MES solutions allow all involved personnel to access real-time jobs that can be performed at any time. With the increasing adoption of Pharma 4.0, pharmaceutical companies are exhibiting a rapid shift to cloud-based solutions. Major MES providers are also taking steps to promote and support this shift. In February 2023, General Electric announced the incorporation of cloud-based MES software in the "Proficy Smart Factory Portfolio."
The manufacturing execution system in life sciences market is segmented on the basis of offering, deployment, organization size, and application. Based on offering, the manufacturing execution system in life sciences market is bifurcated into software and services. In terms of deployment, the manufacturing execution system in life sciences market is segmented into on-premise and cloud. by organization size, the manufacturing execution system in life sciences market is segmented into SMEs and large enterprises. Based on application, the manufacturing execution system in life sciences market is segmented into pharmaceutical, biotechnology, and medical devices. Based on geography, the manufacturing execution system in life sciences market is primarily segmented into North America, Europe, Asia Pacific (APAC), the Middle East & Africa (MEA), and South America (SAM).
Korber AG, Siemens AG, General Electric, Emerson Electric, Schneider, Rockwell Automation, Apprentice FS Inc, ATS Global, Atachi Systems, LZ Lifescience Ltd, POMS Corporation, and Schneider Electric are among the key players in the manufacturing execution system in life sciences market.
Manufacturing execution system in life sciences market players mainly focus on partnerships to create customer value.